Not Just a Viant Play While Viant seems to be the
Post# of 8735
(Total Views: 192)
Posted On: 08/30/2025 5:12:59 PM
Not Just a Viant Play
While Viant seems to be the perfect fit, many other private companies across medtech, biotech, and healthtech sectors could benefit from leveraging BIEL’s public market access. Here are a few that stand out based on recent activity and strategic fit:
Potential Private Companies That Could Leverage BIEL’s Public Market Access
1) Oncotelic Therapeutics: A biopharma innovator with a deep IP portfolio and promising pipeline. Public market access could amplify investor visibility and accelerate funding.
2) VERI Medtech (VRHI): A medical device company with recent insider buying activity. A public listing could support product commercialization and attract institutional capital.
3) Fifty1 Labs: Specializes in AI-driven drug repurposing, including space medicine applications. Public exposure could attract deep-tech and biotech investors.
These companies are either innovating in regulated industries, scaling production, or entering new verticals—making them ideal candidates for a BIEL-style arbitrage strategy. By acquiring or partnering with a publicly traded entity like BIEL, they could bypass traditional IPO hurdles and unlock investor enthusiasm instantly.
While Viant seems to be the perfect fit, many other private companies across medtech, biotech, and healthtech sectors could benefit from leveraging BIEL’s public market access. Here are a few that stand out based on recent activity and strategic fit:
Potential Private Companies That Could Leverage BIEL’s Public Market Access
1) Oncotelic Therapeutics: A biopharma innovator with a deep IP portfolio and promising pipeline. Public market access could amplify investor visibility and accelerate funding.
2) VERI Medtech (VRHI): A medical device company with recent insider buying activity. A public listing could support product commercialization and attract institutional capital.
3) Fifty1 Labs: Specializes in AI-driven drug repurposing, including space medicine applications. Public exposure could attract deep-tech and biotech investors.
These companies are either innovating in regulated industries, scaling production, or entering new verticals—making them ideal candidates for a BIEL-style arbitrage strategy. By acquiring or partnering with a publicly traded entity like BIEL, they could bypass traditional IPO hurdles and unlock investor enthusiasm instantly.
(2)
(0)